Compound class:
Synthetic organic
Comment: Compound 25 is a potent, selective and reversible inhibitor of Bruton's tyrosine kinase (BTK) [2]. It is built on a 4-aminoquinoline scaffold, and has improved drug-like properties (aqueous solubility, potency and stability) compared to previously reported cinnoline scaffold compounds [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Novel BTK inhibitors, like compound 25 are being investigated for their potential to treat autoimmune inflammation [2]. Compound 25 has demonstrated the ability to reduce paw swelling in a rodent collagen-induced arthritis model, which is indicative of potential efficacy in human rheumatoid arthritis. Such compounds are being developed as less toxic alternatives to existing clinically used BTK inhibitors like ibrutinib and acalabrutinib, which would make use in diseases other than cancer more feasible. |